NanoSyrinx Ltd has appointed Thomas J. Farrell as chief executive officer, succeeding founder Joe Healey, who will remain involved in the synthetic biology company, ensuring continuity and scientific leadership. The new CEO brings extensive experience in developing organisations from drug discovery to clinical trials, as NanoSyrinx moves from platform development to building a pipeline of Nanosyringe-enabled biotherapeutics. Mr Farrell was the founding CEO of two NASDAQ-listed companies, raising over $500 million in financing, and oversaw multiple cell and gene therapy product candidates from discovery to clinical trials. Before joining NanoSyrinx, he was president of Oricell Therapeutics, a Shanghai, China-based clinical stage CAR-T company. NanoSyrinx’s technology enables the precise, direct delivery of protein therapeutics into the cytosol of target cells.
NanoSyrinx announced the appointment on 8 January 2026.
Copyright 2026 Evernow Publishing Ltd.